Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance
- Conditions
- High Altitude Effects
- Interventions
- Registration Number
- NCT05575180
- Lead Sponsor
- University of Waterloo
- Brief Summary
A single-centered randomized doubled blinded placebo-controlled cross-over trial comparing two the effect of two carbonic anhydrase inhibitors on exercise performance in acute hypoxia. Participants will be young (under 40 years of age), healthy males and females who are regularly physically active.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Consent provided
- Between ages of 18-40 years old
- In good general health as evidences by medical history
- Perform at least 150 mins of aerobic exercise per week, and engage in physical activity >2 days a week
- Completed in an endurance event in the last 12 months
- Ability to take oral medication, and be willing to adhere to the drug regimen
- Be willing to have blood samples taken
-
Weigh 49kg or less, or are Obese (BMI >30 kg/m2)
-
Presence of chronic health condition (s), being investigated and/or taking prescription medications for the following disorders:
- Cardiovascular - e.g., hypertension
- Metabolic - e.g., type 1 or 2 diabetes
- Respiratory - e.g., chronic obstructive pulmonary disease, asthma
- Digestive - e.g., ulcerative colitis
- Arthritis
- Cancer
-
Presence of any disorder or condition listed in the health screening questionnaire (see section 12.1)
-
Current use of Lonafarnib, Methenamine, Topamax, or steroids/corticosteroids
-
Known allergic reactions/hypersensitivity to carbonic anhydrase inhibitors or sulfonamides
-
Presence of bleeding or clotting disorders
-
Current smoker or cannabis user
-
Pregnant, suspect to be pregnant, currently planning a pregnancy, or nursing
-
Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Methazolamide Methazolamide Pill Drug: Methazolamide Dose: 100 mg b.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral Acetazolamide Acetazolamide 250Mg Tab Drug: Acetazolamide Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral Placebo Placebo Drug: Placebo (microcrystalline cellulose) Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
- Primary Outcome Measures
Name Time Method Time to complete a 5 km time trial after each experimental day (Days 3-5) The time to complete the 5 km time trial is measured after each time trial. The investigators will be blinded until all participants have completed each trial Primary endpoint is the time to complete a 5 km exercise task in the three arms of the trial (acetazolamide, methazolamide, placebo)
- Secondary Outcome Measures
Name Time Method Oxyhemoglobin saturation The average oxyhemoglobin saturation for each time trial km (1-5) for each arm will be determined. The investigators will be blinded until all participants have completed each trial The secondary endpoint oxyhemoglobin saturation will be measured using a pulse oximeter which measure the fraction of hemoglobin bound to oxygen. The value is expressed as a percent and measured continuously
Expired Minute Ventilation The average minute ventilation for each time trial km (1-5) for each arm will be determined. The investigators will be blinded until all participants have completed each trial The secondary endpoint expired minute ventilation will be measured using a flow meter (pneumotach) which measure flow and allows for the calculation of ventilation. The value is expressed in liters per min and measured continuously
Trial Locations
- Locations (1)
University of Waterloo
🇨🇦Waterloo, Ontario, Canada